Rivastigmine
Sold as Exelon. Every FDA application for this active ingredient: 1 branded and 6 generic.
- First approved: Jul 6, 2007
- Applications: 7
- New uses approved: 2
- Complete response letters: 0
Applications
NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jul 6, 2007 | ExelonNDA 22083 · New dosage form | Sandoz | 9 | Marketed |
| Sep 3, 2015 | RivastigmineANDA 204403 | Alvogen | 4 | Discontinued |
| Jun 20, 2018 | RivastigmineANDA 205622 | Mylan Technologies | 2 | Marketed |
| Jan 8, 2019 | RivastigmineANDA 207308 | Amneal Pharms | 2 | Marketed |
| Mar 4, 2019 | RivastigmineANDA 206318 | Zydus Pharms | 1 | Marketed |
| Nov 26, 2019 | RivastigmineANDA 209063 | Breckenridge | 0 | Marketed |
| Sep 23, 2025 | RivastigmineANDA 215445 | Yichang Humanwell | 0 | Marketed |
SandozApplications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Drugs@FDA